Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
暂无分享,去创建一个
A. Levine | N. Pavletich | S. Gorina | P. Kussie | V. Maréchal | B. Elenbaas | J. Moreau
[1] K. Kinzler,et al. Sequence-specific transcriptional activation is essential for growth suppression by p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Levine,et al. The p53 tumour suppressor gene , 1991, Nature.
[3] A. Levine,et al. p53 and E2F-1 cooperate to mediate apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[4] D. Wiley,et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 , 1993, Nature.
[5] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[6] A. Levine,et al. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[7] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[8] H. Hermeking,et al. Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.
[9] S. Triezenberg,et al. Pattern of aromatic and hydrophobic amino acids critical for one of two subdomains of the VP16 transcriptional activator. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[10] S. Stass,et al. The human MDM-2 oncogene is overexpressed in leukemias. , 1993, Blood.
[11] C. Pabo,et al. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.
[12] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[13] A. Levine,et al. The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.
[14] I. Wilson,et al. Structure of anti-peptide antibody complexes. , 1994, Research in immunology.
[15] G. Reifenberger,et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.
[16] W. D. Cress,et al. Critical structural elements of the VP16 transcriptional activation domain. , 1991, Science.
[17] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[18] G. Wahl,et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.
[19] Carissa A. Sanchez,et al. A p53-dependent mouse spindle checkpoint , 1995, Science.
[20] E A Merritt,et al. Raster3D Version 2.0. A program for photorealistic molecular graphics. , 1994, Acta crystallographica. Section D, Biological crystallography.
[21] M. A. Saper,et al. Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.
[22] U. Francke,et al. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line , 1987, Somatic cell and molecular genetics.
[23] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[24] K. Kinzler,et al. Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .
[25] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[26] W. Sellers,et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.
[27] S K Burley,et al. Biochemistry and structural biology of transcription factor IID (TFIID). , 1996, Annual review of biochemistry.
[28] B. Cullen,et al. Genetic analysis indicates that the human foamy virus Bel-1 protein contains a transcription activation domain of the acidic class , 1994, Journal of virology.
[29] R. Hoff,et al. AIDS: modeling epidemic control , 1995, Science.
[30] T. Chan. Deoxyguanosine toxicity on lymphoid cells as a cause for immunosuppression in purine nucleoside phosphorylase deficiency , 1978, Cell.
[31] F A Quiocho,et al. Target enzyme recognition by calmodulin: 2.4 A structure of a calmodulin-peptide complex. , 1992, Science.
[32] P. Kraulis. A program to produce both detailed and schematic plots of protein structures , 1991 .
[33] B. Cullen,et al. Mutational analysis of the transcription activation domain of RelA: identification of a highly synergistic minimal acidic activation module , 1994, Molecular and cellular biology.
[34] R. Tjian,et al. TBP-TAF complexes: selectivity factors for eukaryotic transcription. , 1994, Current opinion in cell biology.
[35] Peter A. Lawrence,et al. Control of Drosophila body pattern by the hunchback morphogen gradient , 1992, Cell.
[36] M. Czisch,et al. Structural and functional analysis of the NF-kappa B p65 C terminus. An acidic and modular transactivation domain with the potential to adopt an alpha-helical conformation. , 1994, The Journal of biological chemistry.
[37] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[38] R. Tjian,et al. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.
[39] F. Smith. Photography and Chronographic Measurements , 1896, Nature.
[40] P. Meltzer,et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. , 1993, Cancer research.
[41] W. Herr,et al. Reconstitution of transcriptional activation domains by reiteration of short peptide segments reveals the modular organization of a glutamine-rich activation domain , 1994, Molecular and cellular biology.
[42] A. Levine,et al. Essential role for p53-mediated transcription in E1A-induced apoptosis. , 1995, Genes & development.
[43] W. Day. Section of Astronomy, Physics and Chemistry of the New York Academy of Sciences , 1901, Science.
[44] K. Zhang. SQUASH - combining constraints for macromolecular phase refinement and extension. , 1993, Acta crystallographica. Section D, Biological crystallography.
[45] S. Lowe,et al. p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.
[46] K. Sharp,et al. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.
[47] J. D. Hays,et al. Evidence for lower productivity in the Antarctic Ocean during the last glaciation , 1991, Nature.
[48] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[49] C. Finlay,et al. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.
[50] D. Baltimore,et al. Modular binding domains in signal transduction proteins , 1995, Cell.
[51] Bert Vogelstein,et al. p53 function and dysfunction , 1992, Cell.
[52] M. Karin,et al. p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.
[53] K. Kinzler,et al. Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.
[54] Y. Sung,et al. Transactivation Ability of p53 Transcriptional Activation Domain Is Directly Related to the Binding Affinity to TATA-binding Protein (*) , 1995, The Journal of Biological Chemistry.
[55] D. George,et al. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.
[56] A. Levine,et al. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.
[57] R. Tjian,et al. A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[58] D. Koshland. Stress for success. , 1991, Science.
[59] Thea D. Tlsty,et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.
[60] S. Triezenberg,et al. Structure and function of transcriptional activation domains. , 1995, Current opinion in genetics & development.
[61] R L Stanfield,et al. Protein-peptide interactions. , 1995, Current opinion in structural biology.
[62] A. Levine,et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.
[63] A. Levine,et al. Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.
[64] M. Imamura,et al. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[65] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[66] Brian W. Matthews,et al. An efficient general-purpose least-squares refinement program for macromolecular structures , 1987 .
[67] Guillermina Lozano,et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.
[68] S. Fields,et al. Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.
[69] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[70] Lawrence A. Donehower,et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.